Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Zozulia AA, Neznamov GG, Siuniakov TS, et al. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2008;108:38-48.
What it found
30 patients received Selank and the rest medazepam, a benzodiazepine. Anti-anxiety effects were reported as similar, with additional anti-fatigue and stimulating effects for Selank. Patients had a shorter half-life of leu-enkephalin in blood, which rose during Selank treatment.
Limitations
Article in Russian. The abstract does not describe randomisation, blinding or a placebo group, so the design is listed here as open-label. Authors include researchers involved in developing Selank.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.